Xvivo Perfusion AB (XVIVO) - Total Assets
Based on the latest financial reports, Xvivo Perfusion AB (XVIVO) holds total assets worth Skr2.53 Billion SEK (≈ $271.93 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Xvivo Perfusion AB - Total Assets Trend (2011–2025)
This chart illustrates how Xvivo Perfusion AB's total assets have evolved over time, based on quarterly financial data. Also see XVIVO market cap overview for the company's overall valuation and market capitalisation.
Xvivo Perfusion AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Xvivo Perfusion AB's total assets of Skr2.53 Billion consist of 29.0% current assets and 71.0% non-current assets. Review Xvivo Perfusion AB balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr292.09 Million | 12.3% |
| Accounts Receivable | Skr147.66 Million | 6.2% |
| Inventory | Skr248.46 Million | 10.5% |
| Property, Plant & Equipment | Skr213.88 Million | 9.0% |
| Intangible Assets | Skr840.29 Million | 35.4% |
| Goodwill | Skr610.06 Million | 25.7% |
Asset Composition Trend (2011–2025)
This chart illustrates how Xvivo Perfusion AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Xvivo Perfusion AB share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xvivo Perfusion AB's current assets represent 29.0% of total assets in 2025, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 12.3% of total assets in 2025, up from 1.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 60.0% of total assets, an increase from 1.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 35.4% of total assets.
Xvivo Perfusion AB Competitors by Total Assets
Key competitors of Xvivo Perfusion AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
TransMedics Group Inc
NASDAQ:TMDX
|
USA | $1.46 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581
|
China | CN¥2.70 Billion |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580
|
China | CN¥1.79 Billion |
Xvivo Perfusion AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.86 | 4.81 | 6.59 |
| Quick Ratio | 2.65 | 3.13 | 5.33 |
| Cash Ratio | 0.00 | 2.01 | 4.54 |
| Working Capital | Skr540.02 Million | Skr612.49 Million | Skr350.28 Million |
Xvivo Perfusion AB - Advanced Valuation Insights
This section examines the relationship between Xvivo Perfusion AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.02 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | -1.2% |
| Total Assets | Skr2.37 Billion |
| Market Capitalization | $849.50 Million USD |
Valuation Analysis
Below Book Valuation: The market values Xvivo Perfusion AB's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Xvivo Perfusion AB's assets decreased by 1.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Xvivo Perfusion AB (2011–2025)
The table below shows the annual total assets of Xvivo Perfusion AB from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr2.37 Billion ≈ $255.49 Million |
-1.19% |
| 2024-12-31 | Skr2.40 Billion ≈ $258.57 Million |
+9.43% |
| 2023-12-31 | Skr2.20 Billion ≈ $236.28 Million |
+26.69% |
| 2022-12-31 | Skr1.73 Billion ≈ $186.51 Million |
+12.35% |
| 2021-12-31 | Skr1.54 Billion ≈ $166.01 Million |
+34.10% |
| 2020-12-31 | Skr1.15 Billion ≈ $123.79 Million |
+81.30% |
| 2019-12-31 | Skr634.49 Million ≈ $68.28 Million |
+8.16% |
| 2018-12-31 | Skr586.61 Million ≈ $63.13 Million |
+8.93% |
| 2017-12-31 | Skr538.54 Million ≈ $57.96 Million |
+54.18% |
| 2016-12-31 | Skr349.30 Million ≈ $37.59 Million |
+71.07% |
| 2015-12-31 | Skr204.18 Million ≈ $21.97 Million |
+1.23% |
| 2014-12-31 | Skr201.70 Million ≈ $21.71 Million |
+58.12% |
| 2013-12-31 | Skr127.56 Million ≈ $13.73 Million |
+11.39% |
| 2012-12-31 | Skr114.52 Million ≈ $12.32 Million |
-18.71% |
| 2011-12-31 | Skr140.88 Million ≈ $15.16 Million |
-- |
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more